Physician profile
Regina L Manes
NPI 1467445312
$2,163.33
in general payments reported to CMS, 2019-2025
12 companies · $365 in 2025
The $365 reported for 2025 was more than what 77% of Vision Therapy providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $294 · 2021: $161 · 2022: $351 · 2023: $160 · 2024: $159 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $409.03 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $335.71 | 2019-2020 | |
| Glaukos Corporation | $328.67 | 2019-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Horizon Therapeutics Plc | $215.80 | 2021-2022 | |
| Alcon Vision LLC | $189.54 | 2023-2025 | Precision7, Total30, Eysuvis |
| Optovue, INC. | $159.87 | 2019-2020 | |
| Visionix USA, INC | $130.55 | 2022 | |
| Kala Pharmaceuticals, INC. | $125.00 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $119.78 | 2022-2024 | Acuvue |
| Topcon Healthcare, INC. | $68.18 | 2023 | |
| Coopervision INC. | $44.56 | 2023-2024 | Myday Contact Lens, Clariti Contact Lens |
| Tarsus Pharmaceuticals, INC. | $36.64 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Manes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.